v3.25.2
Business Combinations - Purchase Price Allocation (Details)
$ in Thousands, $ in Millions
 12 Months Ended
Feb. 07, 2024
CAD ($)
Mar. 31, 2025
CAD ($)
Mar. 31, 2024
CAD ($)
 [1]
Feb. 07, 2024
AUD ($)
Net cash outflows        
Net cash outflows   $ 0 $ (2,539)  
MedReleaf Australia        
Disclosure of detailed information about business combination [line items]        
Percentage of voting equity interests acquired 90.43%     90.43%
Consideration transferred        
Cash paid $ 8,249     $ 9.5
Common shares issued 36,092     41.6
Total purchase price for remaining 90.43% interest 44,341     51.0
Fair value of existing ownership 4,734      
Total fair value of consideration 49,075      
Final fair value of net identifiable assets        
Cash 5,710      
Accounts receivable 4,785      
Inventory 10,464      
Prepaid expenses and other current assets 80      
Property, plant and equipment 1,795      
Identifiable assets acquired 35,834      
Accounts payable and accrued liabilities 10,206      
Income taxes payable 317      
Lease liability 311      
Identifiable liabilities assumed 10,834      
Final purchase price allocation        
Net identifiable assets acquired 25,000      
Goodwill 24,075      
Final purchase price allocation 49,075      
Net cash outflows        
Cash consideration paid (8,249)     $ (9.5)
Cash acquired 5,710      
Net cash outflows (2,539)      
MedReleaf Australia | Licenses        
Final fair value of net identifiable assets        
Intangible assets 5,500      
MedReleaf Australia | Brand        
Final fair value of net identifiable assets        
Intangible assets $ 7,500      
[1] Comparative information has been adjusted due to discontinued operations see Note 8(b).